|
|
2585 Skymark Avenue, Suite 306
Mississauga, Ontario L4W 4L5 Canada
phone:905.629.3822
fax:905.629.0282 |
| Symbol |
NDQ |
| Exchange |
TSX |
| Founded |
0 |
| Employees |
|
|
|
| www.novadaq.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Real-time imaging to assess organs, tissues and vessels during surgery
|
|
| Management |
| Arun Menawat, President and Chief Executive Officer; Rick Mangat, Sr. Vice President and General Manager; John Fengler, Vice President Research and Development; Joe Wery, Vice President Sales; Stephen Purcell, Chief Financial Officer; Mary Kay Baggs, Vice President Marketing and Business Development; Allison Manners, Vice President Regulatory and Clinical Affairs |
|
|
|
|
| Keywords |
| Ophthalmology, eye, vision, imaging, diagnostics, eyes, vision, cardiovascular, heart, Cardiology, cardiac, heart, bypass graft, bypass surgery, neurologic, macular degeneration, imaging, urology, j2008
|
|
|
|
|
| Description |
|
Novadaq develops and commercializes medical devices based on its proprietary imaging platform for the diagnosis and treatment of human vascular, ophthalmic and neurologic diseases and conditions.
|
|
| Products / Services |
Novadaq's SPY Intra-operative Imaging System, commercially available worldwide, enables cardiac surgeons to visually assess coronary vasculature and bypass graft functionality during the course of open-heart bypass surgery. Novadaq's ophthalmic product, the OPTTX System, is aimed at the diagnosis, evaluation, treatment and on-going management of wet age-related macular degeneration (AMD) by using the same core imaging technology that is used in the SPY System. The OPTTX System is currently being evaluated in clinical trials. Novadaq's product for nerve visualization in prostate surgery, LUNA, is designed to enable surgeons to visualize nerve bundles and the lymphatic system during the course of urological procedures, including radical prostatectomy in order to reduce negative outcomes including, but not limited to, impotency.
|
|
| Technology / Differentiation |
| |
|
| Market / Customers |
As of September 2006, 52 SPY Systems have been placed across the U.S. Novadaq generates revenue from procedural licensing fees and disposables (including the imaging agent). There are over 800,000 heart bypass procedures performed annually worldwide, giving Novadaq and its SPY System a market opportunity of more than $400 million.
|
|
| Competitors / Substitutes / Alternatives |
|
|
| Strategy |
|
|
| Funding |
| Novadaq Technologies is a publicly traded company. |
|
| Status |
| Novadaq recently filed an application for 510(k) clearance to market SPY for use in plastic and reconstructive surgery, which could double the size of the products market.
|
|
|
|
| |
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
